Pharmaceutical - SustainabilityNext

Fujirebio Announces CE Marking of the Fully Automated Lumipulse® G Nfl Blood Assay
Business Wire IndiaH.U. Group Holdings Inc., and its wholly owned subsidiary, Fujirebio Holdings, Inc. (hereinafter “Fujirebio”) today announced that Fujirebio Europe N.V. has obtained a CE Certificate of the Lumipulse G NfL Blood assay under the Regulation (EU) 2017/746 on in vitro diagnostic medical devices (IVDR). This CLEIA (chemiluminescent enzyme immunoassay) test allows for the […]
AMWC 2026: Galderma Showcases Category‑leading Innovation With a Comprehensive Portfolio and Holistic, Future‑focused Aesthetic Strategies
Business Wire India Galderma will present nine posters spanning its full aesthetics portfolio at AMWC 2026, highlighting the regenerative benefits of Sculptra®, the long-lasting efficacy of Restylane®, and the advanced clinical performance of Relfydess® (RelabotulinumtoxinA) 1-9 The data reinforce Galderma’s future-focused approach to innovation, addressing emerging patient needs from menopause‑related skin changes to rising interest in body […]
Samsung Bioepis and Epis NexLab Sign Research Collaboration and License Agreement with G2GBIO to Develop Novel Assets Including Long-acting Semaglutide
Business Wire India Samsung Bioepis to receive exclusive license to develop and commercialize two novel assets including long-acting semaglutide using G2GBIO’s proprietary microsphere technology Epis NexLab, a sister company to Samsung Bioepis under Samsung Epis Holdings, also signs the agreement to collaborate in the development of the long-acting microsphere drug delivery platform Samsung Bioepis […]